阿诺医药 ANL 深 沪
交易中 10-13 12:04:36 美东时间
12.185
-2.035
-14.31%
华盛通- 最 高14.20
- 今 开14.20
- 成交量 48.19万股
- 最 低 11.60
- 昨 收 14.22
- 总市值 7.85亿
- 52周最高 17.25
- 市盈率 静 --
- 换手率 0.75%
- 52周最低 0.8786
- 委 比 -95.12%
- 总股本 6439.79万
- 历史最高 19.2999
- 量 比 3.57
- 振 幅 18.28%
- 历史最低 0.8786
- 每 手 1
- 风险率 5.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
HC Wainwright & Co. Reiterates Buy on Adlai Nortye, Maintains $20 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Adlai Nortye (NASDAQ:ANL) with a Buy and maintains $20 price target.
09-08 23:57
Adlai Nortye Redomiciles to Singapore and Updates Nasdaq Identity
Adlai Nortye Ltd. Sponsored ADR ( ($ANL) ) has issued an update. On July 29, 20...
08-19 20:57
Adlai Nortye H1 EPS $(0.04) Up From $(0.19) YoY, Sales $13.056M
Adlai Nortye (NASDAQ:ANL) reported quarterly losses of $(0.04) per share. This is a 78.95 percent increase over losses of $(0.19) per share from the same period last year. The company reported $13.056 million in sales this quarter.
08-14 19:22
Adlai Nortye Submits Clinical Trial Notification To Australia's TGA And Receives Approval From HREC To Commence Phase I Clinical Trial Evaluating AN4035 For Treatment Of CEACAM5-Enriched RAS-Addicted Solid Tumors
First-in-class pan-RAS(ON) ADC is cleared for clinical development Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submissions to U.S. FDA and China NMPA are in process SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Adl...
08-03 19:04
奥赛康：泛RAS(ON)分子胶ASKC189全球I期临床试验完成间歇给药方案首例患者入组
7月16日，奥赛康（002755.SZ）宣布，泛 RAS（ON）分子胶 ASKC189全球一期临床试验再获关键进展： 该 I 期研究已于今年2月完成标准每日一次...
07-17 11:24
Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Tuesday. Shares of Concentrix Corp (NASDAQ:CNXC) fell sharply in pre-market trading after the company reported worse-than-expected second-quarter financial results and cut its FY26 guidance below estima...
06-30 20:03
